Notice of Intent to Sole Source – Oncotype DX Cancer Testing Services
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY HCD WEST
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT941026N0123
NAICS
621511 - Medical Laboratories
Classification Code
Q301
Additional Details
Documents1
The Defense Health Agency Contracting Activity, Healthcare Contracting Division–West, has issued a Special Notice (Procurement Identifier: HT941026N0123) indicating its intent to negotiate and award a firm-fixed-price sole-source contract to EXACT SCIENCES LABORATORIES, LLC. This procurement is for Oncotype DX Cancer Testing Services, specifically supporting the Mike O’Callaghan Military Medical Center located at Nellis Air Force Base in Nevada.
The primary purpose of this contract is to provide the Oncotype DX branded genomic tumor-testing service and its associated report for eligible patients. The scope of work includes the contractor supplying all necessary materials for specimen submission, conducting the required genomic testing at their facility, delivering written test results and interpretations, and returning tissue tumor blocks or unstained slides as stipulated in the contract. These services are critical for supporting clinical decision-making in cancer care at the medical center.
The anticipated period of performance for this contract is from September 16, 2026, through September 15, 2027. Additionally, the contract includes four 12-month option periods and a potential six-month extension, allowing for continuity and flexibility in service provision over several years. The procurement falls under NAICS Code 621511 (Medical Laboratories), with Product Service Code Q301, and is not subject to any set-aside requirements, making it open to all qualified vendors, though the notice specifies a sole-source intent.
The contracting entity is the Defense Health Agency HCD West, a federal office under the Department of Defense. The place of performance is Nellis AFB, Nevada, United States. For further information or to submit capability statements, interested parties may contact Dominic Gonzales ([email protected]) or Brandi Roberts ([email protected]). Although this is not a request for competitive quotations or proposals, the agency will consider capability statements submitted by the response deadline.
This notice is currently inactive and was posted on October 9, 2026, with a response deadline of November 9, 2026. Additional details and attachments can be accessed via the SAM.gov opportunity ID 7da592450c5e48ff9eee4450299858ec.
Contractors evaluating this opportunity should note the specialized nature of the Oncotype DX testing requirement, the sole-source procurement approach, and the long-term contract structure with multiple option periods. The contract is intended to ensure reliable, high-quality genomic testing services for cancer patients at a major military medical facility, supporting the Defense Health Agency’s mission to provide advanced healthcare solutions.